Research News
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
Harnessing the power of artificial intelligence, researchers have identified nearly 200 previously unknown DNA regions linked to a risk of developing glaucoma, findings that could lead to new ways of preventing the disease.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
Research awarded by BrightFocus totals nearly $290 million to date across 25 countries, enabling innovative scientists from around the world to push the boundaries of Alzheimer’s, macular degeneration, and glaucoma research.
